Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
- Mechanism
- Curator reviewed
CX-717 is an ampakine compound. It is a positive allosteric modulator of AMPA receptors. Its action is theorized to be due to the facilitation of transmission at cortical synapses that use glutamate as a neurotransmitter. This in turn may promote plasticity at the synapse, which could translate into better cognitive performance. CX-717 works by allosterically binding to particular receptors in the brain, called AMPA-type glutamate receptors. This boosts the activity of glutamate, a neurotransmitter, and makes it easier to encode memory and to learn. In addition, CX717 could potentially strongly impact the up-regulation of BDNF (brain-derived neurotrophic factor) or NGF (nerve growth factor), two growth factors known to stimulate the formation of new circuitry in the brain associated with forming memory and cognition.
- Primary indication
- Investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.Curator reviewed
- Formula / weight
- C11H11N3O3 · 233.227 g/mol (avg)
- Code names
- CX-717
Resolves to
KFRQROSRKSVROW-UHFFFAOYSA-NSMILESO=C(N1CCOCC1)C1=CC2=NON=C2C=C1What you can answer from here — as of December 23, 2020
Which drugs share a target with CX-717, and which of those have an active Phase 3 trial?